logo

For the Inventor, By the Inventor

New York, NY, United States of America

Nicole Suciu-Foca

This inventor holds 15 USPTO granted patents, primarily in Cancer Immunotherapy. Top assignee: Columbia University. Active years: 1989-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nicole Suciu-Foca. Retrieved from https://idiyas.com/inventor/nicole-suciu-foca

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 15

% Patents Active = 40.0

Average Co-Inventor Count = 2.7

ph-index = 7

Forward Citations = 91(Granted Patents)


Location History:

  • Cliffside Park, NJ (US) (1989 - 2003)
  • New York, NY (US) (2004 - 2020)

Company Filing History:

goldMedal15 out of 2,563 
 
Columbia University
 patents

Years Active: 1989-2020

Loading Chart...
Areas of Expertise:
Cancer Treatment
ILT3 Polypeptides
T Cell Modulation
Anergic T Helper Cells
Tolerogenic Antigen
Antigen Specific T Suppressor Cells
CD166-Expressing Cancer
Diagnosis
Differentiation Antigens
Helper T Lymphocyte Function
15 patents (USPTO):Explore Patents
1. 10765742 - Methods of treating CD166-expressing cancer (2020-09-08),
2. 10670603 - Diagnosis and treatment of cancer expressing ILT3 or ILT3 ligand (2020-06-02),
3. 9822161 - ILT3 polypeptides and uses thereof (2017-11-21),
4. 9696312 - Diagnosis and treatment of cancer expressing ILT3 or ILT3 ligand (2017-07-04),
5. 9150635 - ILT3 polypeptides and uses thereof (2015-10-06),
6. 9078858 - ILT3 polypeptides and uses thereof (2015-07-14),
7. 8299016 - ILT3 polypeptides and uses thereof (2012-10-30),
8. 8207110 - ITL3 polypeptides and uses thereof (2012-06-26),
9. 7144728 - Method of inducing anergic T helper cells (2006-12-05),
10. 6759239 - Methods for generating tolerogenic antigen presenting cells (2004-07-06),
11. 6667175 - Generation of antigen specific T suppressor cells for treatment of rejection (2003-12-23),
12. 5405750 - Differentiation antigen, NDA4, associated with the receptor for B cell (1995-04-11),
13. 5066581 - Differentiation antigen, NDA.sub.3, associated with the receptor for B (1991-11-19),
14. 4818689 - Late differentiation antigen associated with helper T lymphocyte function (1989-04-04),
15. 4816404 - Late differentiation antigens associated with helper T lymphocyte (1989-03-28),

Title: Innovator Spotlight: Nicole Suciu-Foca, Pioneering Cancer Treatment Researcher

Introduction:

Nicole Suciu-Foca is a renowned inventor based in New York, NY, with an impressive portfolio of 15 patents, primarily focused on groundbreaking methods of treating CD166-expressing cancers. Suciu-Foca's innovative work has significantly contributed to the field of cancer research and treatment.

Latest Patents:

1. Methods of treating CD166-expressing cancer: One of Nicole Suciu-Foca's recent patents unveils revolutionary methods for treating CD166-expressing cancers by targeting the innate immune receptor ILT3 and its ligand CD166. These methods focus on inhibiting cancer cell growth and inducing apoptosis, presenting a promising avenue for cancer therapy.

2. Diagnosis and treatment of cancer expressing ILT3 or ILT3 ligand: Another patent by Suciu-Foca addresses the diagnosis and treatment of cancers expressing ILT3 or its ligand. By leveraging ILT3-based therapies, such as ILT3Fc or anti-ILT3 antibodies conjugated with cytotoxic agents, Suciu-Foca's inventions offer novel approaches to combatting specific cancer types.

Career Highlights:

Nicole Suciu-Foca's illustrious career includes significant contributions to Columbia University in the City of New York. Her tenure at this prestigious institution has been marked by innovative research and patent achievements that have shaped the landscape of cancer treatment methodologies.

Collaborations:

Throughout her career, Nicole Suciu-Foca has collaborated with esteemed colleagues, including George Vlad and Raffaello Cortesini. These collaborations have facilitated the exchange of ideas, leading to the development of impactful inventions and advancements in the field of cancer biology.

Conclusion:

In conclusion, Nicole Suciu-Foca's exemplary work as an inventor in the realm of cancer research underscores her dedication to advancing treatment modalities for CD166-expressing cancers. Her inventive approaches and collaborations have positioned her as a trailblazer in the field, with a profound impact on the future of oncology.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…